cael-101
Generic: anselamimab
cael-101: developed by 2 companies · 1 clinical trial tracked. Updated within the last hour.
Development Pipeline (2)
| Company | Phase |
|---|---|
| ALEXION PHARMACEUTICALS, INC. (ALXN) | Phase 3 |
| Fortress Biotech Inc. (FBIO) | Phase 3 |
Clinical Trials (1)
A Phase 3, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of CAEL-101 and Plasma Cell Dyscrasia Treatment Versus Placebo and Plasma Cell Dyscrasia Treatment in Plasma Cell Dyscrasia Treatment Naïve Patients With Mayo Stage IIIa AL Amyloidosis
Frequently asked questions
Who is developing cael-101?
cael-101 is being developed by ALEXION PHARMACEUTICALS, INC., Fortress Biotech Inc..
How many clinical trials involve cael-101?
BioSniper tracks 1 clinical trial involving cael-101.
Get deeper analysis on cael-101
Full trial data, mechanism of action, competitive landscape, and AI-powered insights.
Start Free Analysis